Subscribe

Developments in Antigen-Specific Therapy for Rheumatoid Arthritis

VBCR - June 2013, Volume 2, No 3 - Value Propositions

According to Australian rheumatologist Ranjeny Thomas, MD, Professor of Rheumatology and Head of the Autoimmunity Programme at the University of Queensland Diamantina Institute, by using tolerance-inducing antigen-specific strategies and dendritic cells, the field of rheumatology is moving ever closer to developing more effective immunotherapies that may eventually achieve greater drug specificity with lower toxicity, and perhaps even the potential to develop agents that could control or even prevent rheumatoid arthritis (RA). Currently, 30% of patients with RA do not achieve sustained remission restoration of self-antigen immune tolerance with existing disease-modifying and biologic therapies, and the market for new therapies is predicted to grow to $12 billion annually by 2017.

Some of the recent key developments that Dr Thomas has reviewed include the emergence of anticitrullinated peptide antigens as a valuable biomarker in RA, targeting and injecting dendritic cells for antigen-specific tolerance, and phase 1 and phase 2 clinical trials of oral tolerization of the dnaJp1 peptide. J Musculoskelet Med; February 27, 2013

Related Items
Value Propositions - April 2018
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Value Propositions
Value Propositions - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Value Propositions
Value Propositions - August 2017
VBCR - August 2017, Vol 6, No 3 published on August 23, 2017 in Value Propositions
Value Propositions - June 2017
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Value Propositions
Value Propositions - April 2017
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Value Propositions
Value Propositions - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Value Propositions
Value Propositions - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Value Propositions
Value Propositions - August 2016
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Value Propositions
Value Propositions - June 2016
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Value Propositions
Value Propositions - April 2016
VBCR - April 2016, Vol 5, No 2 published on May 14, 2016 in Value Propositions
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology